The Lp(a) HORIZON trial, a 7-year, phase III, multicenter international study, has delivered a surprising and disappointing result: despite lowering lipoprotein(a) [Lp(a)] levels by a mean of 78%, the novel medication pelacarsen did not reduce the time to major adverse cardiovascular events (MACE) in more than 8,300 adults with established cardiovascular disease across 42 countries. The findings, presented at the American Heart Association’s Scientific Sessions 2026 and simultaneously published in The New England Journal of Medicine and NEJM Evidence, challenge the assumption that aggressively lowering Lp(a) directly translates into cardiovascular risk reduction.
Participants had Lp(a) levels of 70 mg/dL or higher, placing them in the highest 20% globally, and were randomized to receive monthly injections of pelacarsen or placebo. The primary composite outcome included nonfatal heart attack, stroke, urgent revascularization, or cardiovascular death. Across all analyses, including subgroups with Lp(a) of 90 mg/dL or higher, outcomes were statistically neutral. “I cannot avoid the disappointing conclusion – it didn’t work,” said Steven E. Nissen, M.D., FAHA, senior author and chief academic officer of the Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic. “The neutral finding was unexpected and surprising to the medical community.”
Despite the neutral results, researchers emphasize that Lp(a) remains an important risk factor. “This does not mean Lp(a) is irrelevant,” Nissen said. “It means we need more in-depth research to help us fully understand the underlying mechanisms of Lp(a), its interactions with other CVD risk factors and how it does or does not impact cardiovascular outcomes.” He urged patients in ongoing Lp(a) trials not to drop out, noting that three other cardiovascular outcome trials are underway for investigational compounds targeting high Lp(a) in different ways.
The trial’s implications extend to clinical practice. The 2026 multi-society guideline on the management of dyslipidemia recommends that Lp(a) be measured at least once in adulthood. “Measuring Lp(a) is still absolutely worthwhile,” Nissen said. “Lp(a) is an important risk factor for CVD, and high levels usually do not present with any symptoms.” He added that Lp(a) levels, along with blood pressure, cholesterol, and blood sugar, inform prevention and treatment options, and that proactive lifestyle habits should be implemented early.
Safety data showed similar rates of serious adverse events overall (37.3% with pelacarsen vs. 41.1% with placebo), but higher incidences of flu-like symptoms, injection site reactions, and acute allergic reactions, including anaphylaxis in 19 patients on pelacarsen versus none on placebo. About 21% of patients in the pelacarsen group discontinued treatment due to adverse reactions, compared with more than 7% on placebo.
The trial had limitations: it spanned the COVID-19 pandemic, which may have confounded some cardiovascular events, and 78% of participants self-identified as white, with less than 4% of African ancestry—a group with average Lp(a) levels twice as high. Future trials will need broader representation. As Nissen noted, “Together with the results of Lp(a) HORIZON, we will hopefully have a more robust picture about lowering Lp(a) and its relationship to CVD outcomes.” For now, the take-home message is clear: Lp(a) screening remains essential, but lowering it alone may not suffice to prevent cardiovascular events.


